A double-blind, randomized, placebo-controlled trial investigating the efficacy and safety of nerandomilast over at least 52 weeks in patients with fibrosing interstitial lung disease at risk for disease progression (FIBRONEER-ACT)

Principal Investigator

Dr Rachel Hoyles

Contact us

Email: samantha.chilcott@ndm.ox.ac.uk

IRAS number

1014086